How it works
Get started by filling out the online enrollment application to find out if you are eligible for assistance.
NiceRx verifies your eligibility for medication assistance and notifies you if you are pre-qualified. The pharmaceutical company provides your medication for free, and you only pay our service fee.
We will request documents to be submitted by you and your healthcare provider that are required by the pharmaceutical company to complete your enrollment.
Once approved, the pharmaceutical company typically ships a 90-day supply of medication to your home or healthcare provider’s address. Final acceptance is determined by the pharmaceutical company.
Your monthly Imlygic cost savings if eligible
If you are eligible for the Imlygic patient assistance program, the cost of your medication will be free. We only charge $49 per month for each medication, to cover our service fees. You could receive your Imlygic prescription for just $49 a month, regardless of the retail price of your medication.
Am I eligible for the Imlygic patient assistance program?
We will review your application to determine whether you are eligible for the XXXX patient assistance program. Each program has its own eligibility criteria which is set by the pharmaceutical companies, however, the factors considered by most programs are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for the Imlygic patient assistance program?
We make it as easy as possible to apply for the Imlygic patient assistance program. The first step is to complete our enrollment application. Tell us about any medications you are taking, including Imlygic. We will also ask for details about your healthcare provider, insurance, and your household income. This information is required by the pharmaceutical manufacturers who ship your medication.
If we determine that you may be eligible for Imlygic assistance, we will handle the application process for you. We will work directly with your healthcare provider to prepare your application documents. Once we have received the signed application and supporting documents, we will submit them to the patient assistance program on your behalf. Our service continues once you are enrolled in the Imlygic patient assistance program, and we will automatically request your Imlygic medication refills for up to 1 year.
Is NiceRx an Imlygic coupon provider?
We are a service provider that helps eligible individuals access the Imlygic patient assistance program. That means that we do not offer printable Imlygic manufacturer coupons, Imlygic discounts, or free Imlygic samples. We are not an Imlygic coupon provider or Imlygic discount card. Our service extends to assisting eligible individuals to access the medications they need through patient assistance programs.
Can NiceRx help me get Imlygic cheaper if I have insurance?
We may be able to help you to access Imlygic patient assistance in a variety of circumstances. This includes when your insurance company will not pay for your Imlygic medication or if you have a high copay or coinsurance responsibility. We may also be able to help you if you do not have insurance. Please apply online to find out more.
How much does Imlygic cost without insurance?
Imlygic cost without insurance will vary depending on where you buy it. As a guide, Imlygic injectable suspension (1 mpfu/mL) usually costs $70 for 1 milliliter. With NiceRx you will pay a flat monthly fee of $49, regardless of the retail price of your medication.
How much does Imlygic cost with insurance?
The copay for Imlygic with insurance depends on the terms of your healthcare plan. To find out how much this is, your healthcare provider or pharmacist will be able to calculate your copay with your current insurance.
What is Imlygic?
Imlygic, manufactured by Amgen Inc. has an FDA (U.S. Food and Drug Administration) approved Biologic License. Imlygic is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with advanced melanoma recurrent after the initial surgery.
Limitations of use – Imlygic has not been shown to improve overall survival or have an effect on visceral metastases.
What doses of Imlygic are available?
Imlygic is available in injection form, in the following doses: 106 (1 million) PFU per mL, 108 (100 million) PFU per mL in single-use vials.
The recommended starting dose is up to a maximum of 4 mL of Imlygic at a concentration of 106 (1 million) plaque-forming units (PFU) per mL. Subsequent doses should be administered up to 4 mL at a concentration of 108 (100 million) PFU per mL.
Please read the medication guide and always speak with a healthcare professional about any changes to your dose so they can monitor and evaluate your condition.
Imlygic active ingredients
Imlygic contains talimogene laherparepvec, a genetically modified herpes simplex virus type 1, designed to replicate within tumors and produce an immunostimulatory protein called granulocyte-macrophage colony-stimulating factor (GM-CSF). Imlygic causes cell lysis, or death, which ruptures tumors, releasing tumor-derived antigens, which along with GM-CSF, may promote an anti-tumor immune response from the immune system.
Imlygic side effects
The most common side effects of Imlygic in clinical trials include:
- Fatigue, chills, pyrexia
- Influenza-like illness
- Injection site pain
In rare instances, Imlygic can cause more serious side effects. These can include:
- Accidental exposure may lead to transmission of Imlygic and herpetic infection. Close contacts should avoid direct contact with injected lesions, dressings, or body fluids of treated patients. If accidental exposure occurs, exposed individuals should clean the affected area
- Herpetic infection
- Injection site complications
- Immune-mediated events – consider the risks and benefits of Imlygic before starting treatment in patients who have an underlying autoimmune disease or before continuing treatment in patients who develop immune-mediated events
- Plasmacytoma at the injection site – consider the risks and benefits in patients with multiple myeloma or in whom plasmacytoma develops during treatment
- Obstructive airway disorder
Your doctor will assess the benefits of using Imlygic against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Imlygic to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Imlygic drug interactions
Imlygic can interact with other medications. These include:
- Acyclovir or other antiherpetic viral agents
This list is not exhaustive and other prescription drugs may interact with Imlygic.
You should not use Imlygic if you:
- Are allergic to the active ingredient talimogene laherparepvec
- Are allergic to any of the other ingredients in Imlygic
- Are an immunocompromised patient
- Are pregnant or are planning to become pregnant – use an effective method of contraception to prevent pregnancy during treatment
Talk to your caregiver before using Imlygic if you:
- Are taking any of the medications that could interact with Imlygic
- Are breastfeeding or are planning to breastfeed
Imlygic is the trademark brand name for talimogene laherparepvec manufactured by Amgen Inc. A generic version of talimogene laherparepvec is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Imlygic savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.